Adherence to medication in patients with psoriasis: A systematic literature review

British Journal of Dermatology

Volumn 168, Issue 1, 2013, Pages 20-31

  Thorneloe, Rachael J ^a   Bundy, C ^a   Griffiths, C E M ^a   Ashcroft, D M ^a   Cordingley, L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETRETIN; VITAMIN D DERIVATIVE;

BEHAVIOR CHANGE; BIBLIOGRAPHIC DATABASE; CLINICAL PRACTICE; CONSULTATION; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG SURVEILLANCE PROGRAM; ELECTRONIC DATA INTERCHANGE; EMBASE; ETHNICITY; HUMAN; LIFESTYLE MODIFICATION; MEDICAL RESEARCH; MEDICATION EVENT MONITORING SYSTEM; MEDLINE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACY; PHOTOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SELF REPORT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; WEB OF SCIENCE;

HUMANS; LIFE STYLE; MEDICATION ADHERENCE; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS; PSORIASIS; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; STRESS, PSYCHOLOGICAL;

EID: 84872858082     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12039     Document Type: Review

References (70)

1. Fortune DG, Richards HL, Main CJ, Griffiths CEM,. What patients with psoriasis believe about their condition. J Am Acad Dermatol 1998; 39: 196-201.
2. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM,. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-5.
3. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
4. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. Dermatology 2008; 216: 152-5.
5. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
6. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-18.
7. Najarian DJ, Gottlieb AB,. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003; 48: 805-21.
8. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. 2): 14-17.
9. Poikolainen K, Reunala T, Karvonen J, et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 1990; 300: 780-3.
10. Poikolainen K, Reunala T, Karvonen J,. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994; 130: 473-7.
11. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
12. Horne R,. Compliance, adherence and concordance: implications for asthma treatment. Chest 2006; 130: S65-72.
13. Griffiths CEM, Taylor H, Collins SI, et al. The impact of psoriasis guidelines on appropriateness of referral from primary to secondary care: a randomized controlled trial. Br J Dermatol 2006; 155: 393-400.
14. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42.
15. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R,. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895-7.
16. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-36.
17. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
18. Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52: 434-44.
19. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
20. DiMatteo MR,. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200-9.
21. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222: 363-74.
22. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26: 61-7.
23. Ali SM, Brodell RT, Balkrishnan R, Feldman SR,. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol 2007; 143: 912-15.
24. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol 2004; 51: 212-16.
25. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57: 81-3.
26. Yarbrough C, Yentzer BA, Yelverton CB, Feldman SR,. Continued use of home narrowband ultraviolet B light phototherapy for psoriasis after completion of a clinical trial. J Am Acad Dermatol 2009; 60: 877-9.
27. Yentzer BA, Yelverton CB, Pearce DJ, et al. Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. J Am Acad Dermatol 2008; 59: 577-81.
28. de Korte J, Van Onselen J, Kownacki S, et al. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J Eur Acad Dermatol Venereol 2005; 19: 35-41.
29. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR,. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol 2003; 49: 651-4.
30. Storm A, Benfeldt E, Andersen SE, Serup J,. A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol 2008; 59: 975-80.
31. Altobelli E, Marziliano C, Fargnoli MC, et al. Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features. J Eur Acad Dermatol Venereol 2012; 26: 976-82.
32. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
33. Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat 2006; 17: 294-301.
34. Brown KK, Rehmus WE, Kimball AB,. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55: 607-13.
35. Chan SA, Hussain F, Lawson LG, Ormerod AD,. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat 2011; Epub ahead of print [DOI:10.3109/09546634.2011.607425]
36. Fouéré S, Adjadj L, Pawin H,. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005; 19: 2-6.
37. Gokdemir G, Ari S, Köşlü A,. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol 2008; 22: 330-5.
38. Kamangar F, Isip L, Bhutani T, et al. How psoriasis patients perceive, obtain, and use biologic agents: survey from an academic medical center. J Dermatolog Treat 2011; Epub ahead of print [DOI:10.3109/09546634.2011.631979]
39. Kulkarni AS, Balkrishnan R, Camacho FT, et al. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs Dermatol 2004; 3: 661-6.
40. Renzi C, Picardi A, Abeni D, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-42.
41. Ribera M, Dauden E, Puig L, et al. [Design and validation of a questionnaire to measure treatment satisfaction in patients with moderate-to-severe psoriasis: the NEODERMA study]. Actas Dermosifiliogr 2011; 102: 28-38.
42. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-3.
43. Storm A, Andersen SE, Benfeldt E, Serup J,. One in three prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 2008; 59: 27-33.
44. van de Kerkhof PCM, Steegers-Theunissen RPM, Kuipers MV,. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197: 31-6.
45. van de Kerkhof PCM, de Hoop D, de Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-8.
46. van de Kerkhof PCM, Franssen M, de la Brassine M, Kuipers M,. Calcipotriol cream in the morning and ointment in the evening: a novel regimen to improve compliance. J Dermatolog Treat 2001; 12: 75-9.
47. Zaghloul SS, Goodfield MJD,. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-14.
48. Evers AW, Kleinpenning MM, Smits T, et al. Treatment nonadherence and long-term effects of narrowband UV-B therapy in patients with psoriasis. Arch Dermatol 2010; 146: 198-9.
49. Lecha M, Mirada A, Lopez S, Artes M,. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience. J Eur Acad Dermatol Venereol 2005; 19: 414-17.
50. Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat 2012; 23: 261-7.
51. Woolf RT, West SL, Arenas-Hernandez M, et al. Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. Br J Dermatol 2012; 167: 165-73.
52. Duong M, Piroth L, Grappin M, et al. Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens. HIV Clin Trials 2001; 2: 128-35.
53. Evers AWM, Duller P, van de Kerkhof PCM, et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol 2008; 158: 101-8.
54. Morisky DE, Green LW, Levine DM,. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
55. Osterberg L, Blaschke T,. Adherence to medication. N Engl J Med 2005; 353: 487-97.
56. Rudd P, Ahmed S, Zachary V, et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676-85.
57. Horne R, Weinman J,. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555-67.
58. Leventhal H, Diefenbach M, Leventhal EA,. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cognit Ther Res 1992; 16: 143-63.
59. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004; 38: 1357-62.
60. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-44.
61. Radloff LS,. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
62. Goldberg D, Williams P,. A User's Guide to the General Health Questionnaire. Windsor: NFER-Nelson, 1991.
63. Lehane E, McCarthy G,. Intentional and unintentional medication nonadherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007; 44: 1468-77.
64. Weinman J, Petrie KJ, Moss-Morris R, Horne R,. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. Psychol Health 1996; 11: 431-45.
65. Horne R, Weinman J, Hankins M,. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999; 14: 1-24.
66. Hampson SE, Glasgow RE, Toobert DJ,. Personal models of diabetes and their relations to self-care activities. Health Psychol 1990; 9: 632-46.
67. Jessop DC, Rutter DR,. Adherence to asthma medications: the role of illness representations. Psychol Health 2003; 18: 595-612.
68. Bucks RS, Hawkins K, Skinner TC, et al. Adherence to treatment in adolescents with cystic fibrosis: the role of illness perceptions and treatment beliefs. J Pediatr Psychol 2009; 34: 893-902.
69. Horne R, Parham R, Driscoll R, Robinson A,. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 837-44.
70. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.